Rejdak, Konrad Grieb, Paweł
Published in
Current neuropharmacology
As the World faces unprecedented pandemic caused by SARS-CoV-2 virus, repositioning of existing drugs to treatment of COVID-19 disease is urgently awaited, provided that high quality scientific evidence supporting safety and efficacy in this new indication is gathered. Efforts concerning drugs repositioning to COVID-19 were mostly focused on antivi...
Shan, Ling Swaab, Dick F
Published in
Current neuropharmacology
In contrast to that of other monoamine neurotransmitters, the association of the histaminergic system with neuropsychiatric disorders is not well documented. In the last two decades, several clinical studies involved in the development of drugs targeting the histaminergic system have been reported. These include the H3R-antagonist/inverse agonist, ...
Costas, Carmen Faro, Lilian R F
Published in
Current neuropharmacology
Parkinson's disease (PD) is the second most common neurodegenerative disease and is characterized by a significant decrease in dopamine levels, caused by progressive degeneration of the dopaminergic neurons in the nigrostriatal pathway. Multiple mechanisms have been implicated in its pathogenesis, including oxidative stress, neuroinflammation, prot...
Zhang, Xin Xiao, Weiping Zhang, Qing Xia, Ding Gao, Peng Su, Jiabin Yang, Heng Gao, Xinjie Ni, Wei Lei, Yu
...
Published in
Current neuropharmacology
Moyamoya disease (MMD) is a chronic cerebrovascular disease characterized by progressive stenosis of the arteries of the circle of Willis, with the formation of collateral vascular network at the base of the brain. Its clinical manifestations are complicated. Numerous studies have attempted to clarify the clinical features of MMD, including its epi...
Stanzione, Rosita Forte, Maurizio Cotugno, Maria Bianchi, Franca Marchitti, Simona Busceti, Carla Letizia Fornai, Francesco Rubattu, Speranza
Published in
Current neuropharmacology
Uncoupling protein 2 (UCP2) is a mitochondrial protein that acts as an anion carrier. It is involved in the regulation of several processes, including mitochondrial membrane potential, generation of reactive oxygen species within the inner mitochondrial membrane and calcium homeostasis. UCP2 expression can be regulated at different levels: genetic ...
Bonilla-Jaime, Herlinda Sánchez-Salcedo, José Armando Estevez-Cabrera, M Maetzi Molina-Jiménez, Tania Cortes-Altamirano, José Luis Alfaro-Rodríguez, Alfonso
Published in
Current neuropharmacology
Emotional disorders are common comorbid affectations that exacerbate the severity and persistence of chronic pain. Specifically, depressive symptoms can lead to an excessive duration and intensity of pain. Clinical and preclinical studies have been focused on the underlying mechanisms of chronic pain and depression comorbidity and the use of antide...
Mamelak, Mortimer
Published in
Current neuropharmacology
Sodium oxybate (SO) has been in use for many decades to treat narcolepsy with cataplexy. It functions as a weak GABAB agonist but also as an energy source for the brain as a result of its metabolism to succinate and as a powerful antioxidant because of its capacity to induce the formation of NADPH. Its actions at thalamic GABAB receptors can induce...
Safarpour, Soheila Ghasemi-Kasman, Maryam Safarpour, Samaneh Darban, Yasaman Mahdizadeh
Published in
Current neuropharmacology
Phthalates are widely used in the plastics industry. Di-2-Ethylhexyl Phthalate (DEHP) is one of the most important phthalate metabolites that disrupt the function of endocrine glands. Exposure to DEHP causes numerous effects on animals, humans, and the environment. Low doses of DEHP increase neurotoxicity in the nervous system that has arisen deep ...
Saba, Julieta Couselo, Federico López Bruno, Julieta Carniglia, Lila Durand, Daniela Lasaga, Mercedes Caruso, Carla
Published in
Current neuropharmacology
Huntington's disease (HD) is a neurodegenerative genetic disorder caused by a CAG repeat expansion in the huntingtin gene. HD causes motor, cognitive, and behavioral dysfunction. Since no existing treatment affects the course of this disease, new treatments are needed. Inflammation is frequently observed in HD patients before symptom onset. Neuroin...
Abdi, Sadaf Javanmehr, Nima Ghasemi-Kasman, Maryam Bali, Hanie Yavarpour Pirzadeh, Marzieh
Published in
Current neuropharmacology
Alzheimer's disease (AD) is a neurodegenerative impairment mainly recognized by memory loss and cognitive deficits. However, the current therapies against AD are mostly limited to palliative medications, prompting researchers to investigate more efficient therapeutic approaches for AD, such as stem cell therapy. Recent evidence has proposed that ex...
